Journal Article

Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab

Zietse, Michiel, Koch, Birgit C P, Hendrikx, Jeroen J M A, Sleijfer, Stefan, Malmberg, Ruben, Aerts, Joachim G J V, Dumoulin, Daphne W, van der Veldt, Astrid A M, van Leeuwen, Roelof W F

2022

Overview

Immune checkpoint inhibitors have revolutionised cancer treatment by offering durable responses to many patients with solid and haematological cancers. The high prices and increasing use of immune checkpoint inhibitors put considerable strain on health-care budgets globally. This financial strain could jeopardise patients’ access to these anti-cancer therapies. However, substantial evidence suggests that immune checkpoint inhibitors are being administered at doses that exceed the minimum dose required for maximum anti-tumour efficacy. Therefore, investigating and implementing the most cost-effective dosing strategies for immune checkpoint inhibitors are urgently necessary. This Personal View provides an overview of existing data on immune checkpoint inhibitor pharmacology and (novel) dosing strategies for anti-PD-1 therapy with nivolumab and pembrolizumab, with a special focus on cost-effectiveness and saving potential. Furthermore, specific recommendations to guide health-care professionals are provided, through the process of prescribing, rounding, preparing, and administering nivolumab and pembrolizumab in the most practical and cost-effective way possible.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: Antibodies, Monoclonal, Humanized / Blood cancer / Cancer therapies / Cost analysis / Cost control / Dosage / Drug dosages / FDA approval / Hematologic Neoplasms / Hematology, Oncology, and Palliative Medicine / Humans / Immune Checkpoint Inhibitors / Immunotherapy / Lung cancer / Melanoma / Monoclonal antibodies / Nivolumab / Patients / PD-1 protein / Pembrolizumab / Pharmacodynamics / Pharmacokinetics / Targeted cancer therapy / Tumors